全部所有文章
-
聯亞集團創辦人 王長怡博士 受邀於「2021年生技對話論壇（2021 Biotech Dialog Forum）」發表演說
聯亞集團創辦人 王長怡博士 受邀於「2021年生技對話論壇（2021 Biotech Dialog Forum）」發表演說聯亞集團創辦人 王長怡博士 受邀於「2021年生技對話論壇（2021 Biotech Dialog Forum）」發表演說more -
聯亞生技COVID-19疫苗UB-612第三劑分析結果 受試者對武漢病毒株及Delta變異株均產生極高中和抗體效價並優於其他疫苗
聯亞生技COVID-19疫苗UB-612第三劑分析結果 受試者對武漢病毒株及Delta變異株均產生極高中和抗體效價並優於其他疫苗聯亞生技COVID-19疫苗UB-612第三劑分析結果 受試者對武漢病毒株及Delta變異株均產生極高中和抗體效價並優於其他疫苗more -
聯亞生技新冠疫苗UB-612感恩記者會聲明: 銘謝各界批評指教與熱烈迴響
聯亞生技新冠疫苗UB-612感恩記者會聲明: 銘謝各界批評指教與熱烈迴響聯亞生技新冠疫苗UB-612感恩記者會聲明: 銘謝各界批評指教與熱烈迴響more -
United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Cure
United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional CureUnited BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Curemore -
聯生藥評估UB-421對HIV功能性治癒的療效之二期臨床試驗IND獲准
聯生藥評估UB-421對HIV功能性治癒的療效之二期臨床試驗IND獲准聯生藥評估UB-421對HIV功能性治癒的療效之二期臨床試驗IND獲准more
